Post-Cessation Weight Gain Across Smoking Cessation Therapies: A Review of Secondary Analyses from the ZESCA, EVITA, and E3 Trials
International Journal of Environmental Research and Public Health · 2025
DOI: 10.3390/ijerph22121819 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Environmental Research and Public Health, 2025. Verfasst von Audrey Lelièvre und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC H3T 1E2, Canada. Hauptthemen laut MEDLINE: Smoking Cessation, Weight Gain, Smoking Cessation Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Post-cessation weight gain is a barrier to smoking abstinence, yet evidence on the role of e-cigarettes in mitigating this remains limited.
Objective
To examine weight-related effects of e-cigarettes in comparison with established cessation methods.
Methods
We reviewed data from three cessation trials we conducted between 2005 and 2020. In ZESCA and EVITA, patients were randomized to bupropion or varenicline versus placebo. In the E3 trial, participants were randomized to counseling alone or with nicotine or non-nicotine e-cigarettes. Post hoc analyses assessed weight at 52 weeks for bupropion and varenicline, and 12 weeks for e-cigarettes. Synthesis: Abstinent individuals showed significant weight gain from baseline across the trials. In ZESCA and EVITA, abstinent participants gained more weight than intermittent and persistent smokers at 52 weeks (ZESCA: 4.8 vs. 2.0 vs. 3.0 kg, EVITA: 4.8 vs. 2.0 vs. −0.7 kg, respectively). Abstinent individuals gained more weight than persistent smokers (ZESCA: 3.4 kg, EVITA: 5.5 kg). In the E3 trial, abstinent participants with nicotine e-cigarettes gained more weight than those using non-nicotine e-cigarettes or counseling at 12 weeks (2.7 vs. 2.3 vs. 2.1 kg, respectively).
Conclusions
Abstinent individuals experienced significant weight gain regardless of cessation treatment. Long-term effects of e-cigarettes on weight remain unclear.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC H3T 1E2, Canada.
- Faculty of Medicine, McGill University, Montreal, QC H3G 2M1, Canada.
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC H3A 1Y7, Canada.
- Departments of Medicine and of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC H3A 1Y7, Canada.
- Division of Cardiology, Jewish General Hospital/McGill University, Montreal, QC H3T 1E2, Canada.
ORCID-Profile: Mark J Eisenberg
Zitieren
APA
Lelièvre, A., Zolotarova, T., & Eisenberg, M. J. (2025). Post-Cessation Weight Gain Across Smoking Cessation Therapies: A Review of Secondary Analyses from the ZESCA, EVITA, and E3 Trials. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph22121819
Vancouver
Lelièvre A, Zolotarova T, Eisenberg MJ. Post-Cessation Weight Gain Across Smoking Cessation Therapies: A Review of Secondary Analyses from the ZESCA, EVITA, and E3 Trials. International Journal of Environmental Research and Public Health. 2025. doi:10.3390/ijerph22121819
BibTeX
@article{Lelivre2025,
author = {Lelièvre, Audrey and Zolotarova, Tetiana and Eisenberg, Mark J},
title = {Post-Cessation Weight Gain Across Smoking Cessation Therapies: A Review of Secondary Analyses from the ZESCA, EVITA, and E3 Trials},
journal = {International Journal of Environmental Research and Public Health},
year = {2025},
doi = {10.3390/ijerph22121819}
}
EUVIMED